9th Annual Cell Line Development & Engineering Asia & 10th Annual Biomanufacturing Agenda

Day 1: 3 November 2020


Joint Opening Plenary


13:00
Opening Address:
China’s Big Leap towards BioPharma 2030 – Innovation, Industrialization, Internationalization

Dr. Song Ru Lin, Executive President, China Pharmaceutical Innovation and Research Development Association (PhIRDA), China

13:30
Keynote Address:
China’s Biopharma Capital Markets – Future Funds and Innovative Financing

Fu Wei, Chief Executive Officer, CBC Group, China

14:00
Online Networking & Stretch Break

14:15
Venture Capitals’ Roundtable:  
Show Me the Drug

  • Investment landscape in the Chinese biopharma market
  • Evaluating drug pipelines and development prospects
  • Mergers, expansion and JVs – Where do we see transactions picking up?
  • Financing new plants, new therapeutics, product launch and scaling-up operations – How do we review?
  • Manufacturing 4.0 – How do VCs and banks play a part in modernising the value chain?

Moderator:
Fu Wei, Chief Executive Officer, CBC Group, China

Panelists:
Rani Jarkas, Chairman, Cedrus Group, Hong Kong
Judith Li, Partner, Lilly Asia Ventures, China
Dr. Karen Liu, Founding Partner, 3E Bioventures Capital, China
Lynn Yang, Managing Director, Sequoia Capital, China

14:55
INDUSTRY SPOTLIGHT:
Enhancing Complex Protein Expression with Highly Efficient Gene Integration Technology

Dr. Allison Porter, Head of Expression System Sciences, Lonza Pharma & Biotech, U.K.

15:25
Online Networking & Stretch Break


End of Joint Opening Plenary and 9th Annual Cell Line Development & Engineering Asia & 10th Annual Biomanufacturing commences

Optimising Workflows And Bioprocesses


15:40
Debottlenecking and Process Optimisation in China BioPharma Landscape

  • Rate-limiting steps in China biopharma’s facilities and what are the solutions
  • Data, complexity and variability in biomanufacturing
  • Advances in bioprocess monitoring and analytics, and bioinformatics and computational biology in China

Dr. Simon Hsu, Senior Vice President, Technical Operations, Henlius, China

16:10
Integrated Cell Line Development Strategy in Whole CMC Picture

  • How to evaluate a CHO based expression systems?
  • Can the cell line generation work be integrated with other process?
  • How to achieve cell lines with high quality and stability under fast workflow?

Xi Chen, Director, Cell Engineering, Qilu Pharmaceuticals, China

16:40
Accelerating CLD for Commercial Success

Dr. Pan Zhiwei, Senior Director, Process Development, Junshi Pharma, China

17:10
End of Conference Day 1

Day 2: 4 November 2020


Novel Advances In CLD Techniques & Technology


13:00
Next-Generation Cell Line Development with Accelerated Timeline and High Productivity

  • Cell line development strategy for accelerated Covid-19 program approval
  • Codon impact on productivity
  • Next-generation sequencing application in cell line development

Zheng Zhang, Director II, Cell Line Development, WuXi Biologics, China

13:30
Single Cell Confidence – Creating the Double Lock of Assurance

Mark Stockdale, Amalgamator of Business and Biology, Solentim, UK

14:00
Using Recombinant Insulin in DoE for Media Development

  • Case study
  • Insulin – CHO Mab
  • Insulin – HEK293 Influenza Virus

Chantale Julien, Global Product Manager, Novo Nordisk Pharmatech, Denmark

14:30
Online Networking & Stretch Break

15:00
Case Study

Dr. Vicky Goralczyk, Director, Cell Line and Bioprocess Development, Glycotope, Germany  

15:30
Next-Generation Cell Line Development Platform for Advanced Bispecific Antibodies Expression

Dr. Séverine Fagète, Vice President, Cell Line Development Services, JSR Life Sciences, Switzerland


Innovative Bioprocess Development


16:00
Powder Handling and Hydration in Upstream Processes  

  • Evaluation of powder transfer bag designs for solid media and buffer handling
  • Trusted Weight Bags and streamlining incoming sampling requirements
  • Novel method for eliminating vortex mixing of powders
  • Supply chain security and supplier performance for a single use supplier

Scott Patterson, Vice President, Pharma / Biopharma, Technical Support, ILC Dover, Singapore

16:30
CMC development of Antibody Drug Conjugates

  • ADC introduction + ADC CMC challenge and approach

Dr. Huang Peng, Project Leader, ADC, TOT Biopharm, China

17:00
End of Conference Day 2

Day 3: 5 November 2020


Biomanufacturing 2030 – China’s Great Leap


13:00
Scaling Up the Commercial Production of mAb Therapeutics in China

  • China’s capacity outlook and how do we capitalize on the mAb therapeutics markets
  • Teruisi’s breakthrough of mAb’s tech transfer and large-scale production in China while in-line with international standards – challenges and key learnings
  • Manufacture showcase to improve cost and efficiency

Dr. Wu You Ling, Chief Executive Officer, Zhejiang Teruisi Pharmaceuticals, China

13:30
Build vs. Buy – Long-term View of Capacity, Supply-Demand Balance and Investment in China’s Manufacturing Facilities

  • Insights on biopharma market segments driving new growth and where is the supply and demand
  • Identifying new market for biomanufacturing – emerging locations and site selection strategy
  • Manufacturing capacity outlook – utilization rates, new investment and a medium-term position
  • Commercial phase market outlook for CDMOs in China

Fireside Chat:
Jeff Li, General Manager, Lonza Pharma Biotech and Nutrition, China
Dr. Zhang Zhe Ru, President, Head of CMC and Manufacturing, I-MAB Biopharma, China

14:00
Online Networking & Stretch Break


Future Facilities & Smart Biomanufacturing


14:30
Tools and Best Practices for Successful Technology Transfer

Mahalia Corrales, Senior Director, Process Development & Technology, JHL Biotech, Taiwan

15:00
Manufacturing Technology Showcases – Improving Cost and Efficiency

  • Next gen manufacturing facilities design and investment trends
  • Smart automation case studies to increase facility efficiency and cost optimization
  • Intelligent bioreactors – advantages and benefits

Frank Ye, Senior Vice President, Technical Operations, Transcenta, China

15:30
Biomanufacturing Process Validation and Quality Risk Management

  • New process concepts of CQAs, CPPs, and QbDs
  • Best practices on quality risk management in bioprocess development
  • Case study on Bio-Thera’s manufacturing process quality control on the newest Humira biosimilar

Bao Cai, Senior Director, Manufacturing, Bio-Thera Solutions, China

16:00
End of Conference Day 3